Ovid Therapeutics (OVID) Amortization of Deferred Charges (2022 - 2026)
Ovid Therapeutics (OVID) posted Amortization of Deferred Charges of $312000.0 for Q1 2026, up 2.3% on a QoQ basis from $305000.0 in Q4 2025, and up 8.33% year-over-year from $288000.0 in Q1 2025.
Ovid Therapeutics (OVID) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
Ovid Therapeutics' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $312000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges rose 8.33% year-over-year to $312000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 8.22% YoY) and the FY2025 annual result came in at $1.2 million, up 8.2% from the prior year.
- Amortization of Deferred Charges was $312000.0 for Q1 2026 at Ovid Therapeutics, up from $305000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $354185.0 in Q2 2022 and bottomed at $253000.0 in Q1 2023.
- A 5-year average of $280818.8 and a median of $274500.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges declined 27.16% — and 2026, when it gained 8.33%.
- Ovid Therapeutics' Amortization of Deferred Charges stood at $254970.0 in 2022, then increased by 2.36% to $261000.0 in 2023, then rose by 8.05% to $282000.0 in 2024, then rose by 8.16% to $305000.0 in 2025, then grew by 2.3% to $312000.0 in 2026.
- Business Quant data shows OVID's Amortization of Deferred Charges at $312000.0 in Q1 2026, $305000.0 in Q4 2025, and $300000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 312,000.00 |
| Mar 31, 2026 | 312,000.00 |
| Dec 31, 2025 | 305,000.00 |
| Dec 31, 2025 | 305,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 294,000.00 |
| Jun 30, 2025 | 294,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Dec 31, 2024 | 282,000.00 |
| Dec 31, 2024 | 282,000.00 |
| Sep 30, 2024 | 277,000.00 |
| Sep 30, 2024 | 277,000.00 |
| Jun 30, 2024 | 272,000.00 |
| Jun 30, 2024 | 272,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Dec 31, 2023 | 261,000.00 |
| Dec 31, 2023 | 261,000.00 |